Share General Information
Nusinersen is an antisense oligonucleotide that induces SMN protein expression. Nusinersen was developed in 2016 for the treatment of spinal muscular atrophy (SMA), a rare neuromuscular disorder.
About the API
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
